ArticleMolecular diversity2026
First structural Elucidation of Bcl-2 functional conversion induced by validated modulators using microsecond-scale molecular dynamics simulations and density functional theory.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of mortality worldwide, largely driven by uncontrolled cell proliferation and the evasion of apoptosis, a tightly regulated process essential for cellular homeostasis. The Bcl-2 family of proteins plays a central role in regulating the intrinsic apoptotic pathway, with anti-apoptotic Bcl-2 promoting cell survival by sequestering pro-apoptotic Bax. Although Bcl-2 functional converters (BFCs) have been experimentally validated to reprogram Bcl-2 toward a pro-apoptotic function, the molecular-level structural and dynamic mechanisms underlying this functional conversion remain poorly understood. In particular, direct atomistic evidence explaining how targeting the intrinsically flexible loop domain drives conformational switching in Bcl-2 is still lacking. To address this critical gap, the present study provides the first structural and dynamic insights into FLD-mediated functional conversion of Bcl-2 using representative synthetic, experimentally validated BFCs (BFC1103 & BFC1108). Molecular docking followed by atomistic microsecond-scale MD simulations was employed to delineate binding stability and conformational changes. Extensive docking analyses revealed strong binding affinity and persistent non-covalent interactions with key FLD residues. Long-timescale atomistic MD simulations demonstrated that FLD engagement induces pronounced conformational changes in Bcl-2, resulting in BH3 domain exposure and a Bax-like, pro-apoptotic structural state. Collectively, this work establishes a first-of-its-kind structural frame work that links FLD targeting to Bcl-2 functional conversion, thereby bridging experimental observations with atomistic simulations and providing a rational basis for the design of next-generation apoptosis-restoring anticancer therapeutics.
Indexed as
Identifiers
41706293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.